Metabolism Disorder TRIZ Cases

Fully human monoclonal antibodies block PCSK9 binding to LDL receptors, restoring cellular uptake and reducing circulating LDL-C concentrations.

A virus-like particle immunogen elicits antibody responses against angiopoietin-like polypeptides to inhibit lipoprotein lipase activity.

Segmenting ACAT isoforms preserves cholesterol homeostasis while treating obesity.

S-nitrosylating agents restore VLCAD enzymatic activity, reducing liver triglycerides and treating very long-chain acyl-CoA dehydrogenase deficiency.

Recombinant adeno-associated viral vectors deliver the GLA gene to target tissues, enabling sustained alpha-GAL enzyme production.

Intrathecal recombinant iduronate-2-sulfatase administration delivers therapeutic enzyme directly to the central nervous system.

Mutating residues 24, 25, and 27 in glucagon analogs prevents fibrillation and deamidation at physiological pH.

Chimeric trigonal agonists merge exendin-4 with glucagon sequences to enhance solubility, stability, and multi-receptor activation efficacy.

Withholding valine in parenteral or enteral formulas eliminates hematopoietic stem cells without radiation-induced tissue damage.

A molecular probe targets pancreatic islets via GLP-1R binding for PET or SPECT imaging.

Monoclonal antibodies neutralize ANGPTL3 activity to lower serum lipid concentrations, addressing underlying metabolic dysfunction in hypertriglyceridemia.

Aromatic-cationic peptides treat metabolic syndrome by improving lipid metabolism and blood sugar levels.

Hydroquinone ansamycins resolve low solubility and hepatotoxicity of geldanamycin by adding hydroxyl groups to improve delivery.

Novel glucagon analogue peptides act as dual agonists for glucagon and GLP-1 receptors to modulate metabolic functions.

Lactobacillus plantarum LP10 reduces body fat without adverse effects by mediating lipid metabolism at dosages exceeding 3×10^10 CFU daily.

Agglomerated amphiphilic polymer microparticles prevent initial burst and sustain release of hydrophilic drugs via controlled degradation.

Anti-PCSK9 antibodies target pathological protein activity to lower serum LDL cholesterol levels in patients with autosomal dominant hypercholesterolemia.

Cardiosphere-derived exosomes reduce inflammation and fibrosis, addressing limited efficacy of corticosteroids in chronic GVHD.

Negative modulator antibody fragments block insulin-receptor binding to prevent recurrent hypoglycemia and improve glycemic control.

Liver-targeting nanoparticles deliver SHP2 inhibitors to alleviate insulin resistance while minimizing off-target toxicity.

Amino acid modifications in GLP-1 polypeptides resolve the trade-off between glucose lowering and cardiorenal protection.

64Zn-enriched zinc reduces liver inflammation and fat accumulation while minimizing toxic side effects associated with traditional therapies.

Segmenting CB1 receptors via large molecule antibodies blocks peripheral signaling without CNS penetration, reducing adverse effects.

Culturing somatic cells with specific small molecule compounds induces direct differentiation into functional insulin-producing cells.

Modified recombinant alpha-galactosidase A improves GL-3 elimination and cardiac response by increasing lysosomal retention through optimized glycosylation.

A modified parathyroid hormone compound maintains serum calcium levels while preserving bone integrity in hypoparathyroidism patients.

GDNF receptor agonists protect islet cells from storage-induced apoptosis, increasing transplant viability and reducing donor organ requirements.

Bone Morphogenetic Protein 7 converts non-endocrine pancreatic tissue into insulin-producing islet-like cell clusters.

A pharmaceutical composition containing resveratrol, glycine, arginine, and cysteine reduces body fat and glucose levels.

Administering relaxin preserves pancreatic beta-cell function and regulates blood sugar levels through improved insulin sensitivity.

GCGR-binding antibodies block glucagon signaling to resolve inadequate blood glucose regulation in diabetes treatment.

Pharmacological chaperone migalastat stabilizes mutant alpha-galactosidase A enzyme activity to reduce substrate accumulation in pediatric patients.

Amino acid substitutions in oxyntomodulin analogues extend duration of action and reduce clearance rates for sustained appetite suppression.

A Salvia Miltiorrhiza composition enhances exercise tolerance and delays ST-segment depression in stable angina patients.

MCT compositions bypass compromised beta-oxidation to treat degenerative mitral valve disease without diuretic side effects.

C-terminal deletion reduces GDE transgene size to fit single AAV vectors, enabling long-term glycogen storage disease III treatment.

Injectable statins inhibit HMG-CoA reductase to induce adipocyte death, eliminating anesthesia risks associated with liposuction.

Red yeast rice extract lowers cholesterol without hepatotoxicity or myopathy risks common to synthetic statins.

Co-culturing CD14+ cells with mesenchymal stem cells generates anti-inflammatory macrophages, bypassing weeks of direct MSC expansion to reduce treatment time.

Dual NLRP1 and NLRP3 inhibitors prevent compensatory activation by blocking both pathways concurrently, reducing IL-1β and IL-18 expression.

Specific omega fatty acid ratios in animal compositions reduce MAP kinase activity to treat cancer and tissue hyperplasia.

Covalent attachment of two PEG molecules to GLP-1 peptides reduces DPP-IV clearance and prevents storage separation, lowering nausea side effects.

Segmenting Semaglutide into smaller peptide fragments reduces impurity formation during synthesis, enabling high-yield purification via reverse phase HPLC.

Optimized cyanoborohydride concentrations resolve the yield versus circulation time contradiction, enabling high-purity long-acting formulations.

Choline geranate ionic liquid enhances active compound permeation across biological membranes.

Novel proinsulin glargine structure with SOD fusion peptide enhances fermentation yield by 75%.

Osmotic delivery systems sustain GLP-1 agonist release to starve cancer cells of glycolytic energy, overcoming limited therapeutic options.

A specific peptide composition promotes cellular calcium absorption to treat bone density loss.